Climara vs. Bijuve
See how Climara and Bijuve compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Climara is a once-weekly estrogen-only patch, while Bijuve is a once-daily capsule combining estradiol with progesterone in a single dose.
Both carry the same boxed warnings for blood clots, stroke, heart attack, dementia risk, and endometrial or breast cancer risk.
Climara covers a broader range of menopause-related uses, while Bijuve is approved only for hot flashes in women who still have a uterus.
Climara vs. Bijuve Drug Summary
Climara
Climara is a steroidal estrogen patch used for hormone replacement therapy. It treats hot flashes, vaginal atrophy, and hypoestrogenism from menopause or ovarian failure, and helps prevent postmenopausal osteoporosis. It is applied to the skin once a week in one of six doses.
Bijuve
Bijuve is a combination hormone capsule containing bioidentical estradiol and progesterone. It treats moderate to severe hot flashes caused by menopause in women who still have a uterus. It comes in two strengths and is taken by mouth once a day.
Climara vs. Bijuve Side Effects
Climara
Bijuve
Climara vs. Bijuve Dosage
Climara
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 0.025 mg/day patch | At the start |
| Maximum dose | 0.1 mg/day patch | If needed |
| Dose changes | 5 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg | At the start |
| Maximum dose | 1 mg/100 mg | If needed |
| Dose changes | 1 increase | As tolerated |
Climara
| STAGE | DOSE | WHEN |
| Starting dose | 0.025 mg/day patch | At the start |
| Maximum dose | 0.1 mg/day patch | If needed |
| Dose changes | 5 increases | As tolerated |
Bijuve
| STAGE | DOSE | WHEN |
| Starting dose | 0.5 mg/100 mg | At the start |
| Maximum dose | 1 mg/100 mg | If needed |
| Dose changes | 1 increase | As tolerated |
Climara vs. Bijuve Indications
Climara
Climara is FDA-approved for hot flashes, vaginal and vulvar atrophy, and low estrogen levels from menopause, ovarian failure, hypogonadism, or castration. It is also approved to help prevent bone loss after menopause. Some clinicians prescribe it off-label as part of feminizing hormone therapy for transgender women.
Moderate to severe hot flashes from menopause
Vulvar and vaginal atrophy from menopause
Hypoestrogenism from hypogonadism, castration, or ovarian failure
Prevention of postmenopausal osteoporosis
Off-label: feminizing hormone therapy for transgender women
Bijuve
Bijuve is FDA-approved only for moderate to severe hot flashes caused by menopause, and only in women who still have a uterus. It pairs bioidentical estradiol with bioidentical progesterone in one capsule, so a separate progestin pill is not needed. It is not approved for women without a uterus or for preventing heart disease, stroke, or dementia.
Moderate to severe hot flashes from menopause
Only approved for women with an intact uterus
Combines estradiol and progesterone in one capsule
Not approved for osteoporosis prevention
Not approved for women without a uterus
Climara vs. Bijuve Pros and Cons
Climara
Climara's transdermal delivery skips first-pass liver metabolism, which may lower clot risk compared with oral estrogens. It offers six patch strengths for fine-tuned dosing and covers a wider range of approved uses than Bijuve. Because it contains only estrogen, women with a uterus need to add a separate progestogen to protect against endometrial cancer.
Pros
Once-weekly patch instead of a daily pill
Transdermal route may carry lower clot risk than oral estrogen
Six dose strengths allow more precise titration
Cons
Estrogen-only formula requires an added progestogen for uterus protection
Patch can loosen with sweating, bathing, or exercise
Requires remembering to rotate and change the patch weekly
Bijuve
Bijuve combines bioidentical estradiol and progesterone into one daily capsule, so women with a uterus do not need a second progestin prescription. It is approved for hot flashes only and is not indicated for osteoporosis prevention or for women without a uterus. Because it is swallowed, it passes through the liver first, which can raise clotting risk compared with a patch.
Pros
Single capsule provides both estrogen and progesterone
No need for a separate progestin prescription in women with a uterus
Only FDA-approved bioidentical estradiol-progesterone combination capsule
Cons
Oral dosing passes through the liver first, which may raise clot risk
Approved only for hot flashes, a narrower use than Climara
Not approved for women without a uterus
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.